This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Healthcare ETFs to Ride on UnitedHealth's Solid Q2 & Outlook
by Sweta Killa
Investors should tap the opportunity with ETFs having the largest allocation to UnitedHealth.
4 Sector ETFs Braved Trade Turmoil in Q2
by Sanghamitra Saha
Sector ETFs that have won in Q2 braving a host of issues.
3 Medical ETFs & Stocks Prescribed on Health Day
by Sanghamitra Saha
How healthcare ETFs are shaping up this year amid tech and trade-induced turmoil.
Trump's 2019 Budget Blueprint: ETF Winners & Losers
by Sanghamitra Saha
Trump's 2019 budget blueprint puts these ETFs in focus.
3 ETF Areas May Come Under Pressure on Tax Reform
by Sanghamitra Saha
These ETF areas may not profit out of Trump's tax reform.
Sector ETFs to Win on Strong November Job Data (Revised)
by Neena Mishra
These sector ETFs may win over the medium-term on decent job growth.
4 ETFs to Gain From CVS-Aetna Deal
by Sweta Killa
These ETFs will benefit most from the potential buyout of Aetna by CVS Health.
Top-Ranked ETFs in Focus on Rumored CVS-Aetna Deal
by Sweta Killa
The biggest story on Wall Street is the potential buyout of Aetna by CVS Health Corp.
Ride On UnitedHealth Q3 Strength with These ETFs
by Sanghamitra Saha
Play upbeat earnings of UnitedHealth Group with these ETFs.
Trump Wins Healthcare Vote: ETFs to Watch
by Sweta Killa
The bill is expected to cut billions of dollars in health-care spending and result in millions of Americans going without health insurance.
Stocks to Watch Ahead of GOP Healthcare Vote
by Ryan McQueeney
Lawmakers are scheduled to vote on the GOP's repeal-and-replace healthcare bill this afternoon. Here are some major stocks to watch as investors react to the vote.
5 ETFs to Buy if Trump Tax Reform is Enacted by Year End
by Sanghamitra Saha
Trump Tax Reform Plans Put These ETFs in Focus.
Forget Earnings: Play Revenue Growth with 4 ETFs
by Sanghamitra Saha
Why to put more stress on revenue cycle this earnings season and play these ETFs.
Health Insurance Industry Outlook - February 2017
by Zacks Equity Research
The overall uncertain outlook for Obamacare and final regulatory shape of this space continues to be a headwind for the sector as a whole.